Video

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

It is exciting to see precision medicine truly take hold in prostate cancer, says Hamid. Historically, clinically driven parameters such as volume of metastatic disease were used to indicate which subpopulations of patients benefit from chemotherapy versus those that do not. Now, the field can use biological parameters to guide more precise treatment decisions.

Precision medicine is becoming more apparent across oncology with the use of clinical information, biological information, and drug response information, among other things, concludes Hamid.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System